JPWO2020163225A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163225A5 JPWO2020163225A5 JP2021545378A JP2021545378A JPWO2020163225A5 JP WO2020163225 A5 JPWO2020163225 A5 JP WO2020163225A5 JP 2021545378 A JP2021545378 A JP 2021545378A JP 2021545378 A JP2021545378 A JP 2021545378A JP WO2020163225 A5 JPWO2020163225 A5 JP WO2020163225A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cancer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025021046A JP2025072613A (ja) | 2019-02-05 | 2025-02-12 | 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801590P | 2019-02-05 | 2019-02-05 | |
| US62/801,590 | 2019-02-05 | ||
| US201962824923P | 2019-03-27 | 2019-03-27 | |
| US62/824,923 | 2019-03-27 | ||
| US201962879660P | 2019-07-29 | 2019-07-29 | |
| US62/879,660 | 2019-07-29 | ||
| US201962882016P | 2019-08-02 | 2019-08-02 | |
| US62/882,016 | 2019-08-02 | ||
| US201962934424P | 2019-11-12 | 2019-11-12 | |
| US62/934,424 | 2019-11-12 | ||
| PCT/US2020/016381 WO2020163225A1 (en) | 2019-02-05 | 2020-02-03 | Anti-cd228 antibodies and antibody-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021046A Division JP2025072613A (ja) | 2019-02-05 | 2025-02-12 | 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519273A JP2022519273A (ja) | 2022-03-22 |
| JPWO2020163225A5 true JPWO2020163225A5 (enExample) | 2023-02-13 |
| JP7754715B2 JP7754715B2 (ja) | 2025-10-15 |
Family
ID=69740807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545378A Active JP7754715B2 (ja) | 2019-02-05 | 2020-02-03 | 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート |
| JP2025021046A Withdrawn JP2025072613A (ja) | 2019-02-05 | 2025-02-12 | 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021046A Withdrawn JP2025072613A (ja) | 2019-02-05 | 2025-02-12 | 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11617798B2 (enExample) |
| EP (1) | EP3920968A1 (enExample) |
| JP (2) | JP7754715B2 (enExample) |
| KR (1) | KR20210125511A (enExample) |
| CN (1) | CN113710271B (enExample) |
| AU (1) | AU2020219732A1 (enExample) |
| BR (1) | BR112021015477A2 (enExample) |
| IL (1) | IL284974A (enExample) |
| MX (1) | MX2021009138A (enExample) |
| SG (1) | SG11202107551WA (enExample) |
| TW (1) | TWI872044B (enExample) |
| WO (1) | WO2020163225A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3176248A1 (en) | 2020-04-10 | 2021-10-14 | Seagen Inc. | Charge variant linkers |
| EP4240415A1 (en) | 2020-11-08 | 2023-09-13 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
| CA3221398A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
| PE20242179A1 (es) | 2022-03-17 | 2024-11-07 | Seagen Inc | Conjugados de camptotecina |
| CA3252067A1 (en) * | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory Antibody-Drug Conjugates |
| JP2025504566A (ja) * | 2022-05-31 | 2025-02-12 | 山東博安生物技術股▲ふん▼有限公司 | 抗ｃｄ２２８抗体およびその薬物コンジュゲート |
| TW202428603A (zh) * | 2022-09-21 | 2024-07-16 | 美商思進公司 | 新穎的cd137及cd228特異性融合蛋白 |
| KR20250069943A (ko) * | 2022-09-21 | 2025-05-20 | 씨젠 인크. | Cd228과 결합하는 항체 |
| WO2025025731A1 (zh) * | 2023-07-28 | 2025-02-06 | 山东博安生物技术股份有限公司 | 一种适用于免疫组化检测cd228的诊断抗体 |
| WO2025090774A1 (en) | 2023-10-24 | 2025-05-01 | Seagen Inc. | Chemotherapeutic compounds and methods of use |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| EP0428534B1 (en) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| DE69130709T3 (de) | 1990-10-05 | 2005-12-22 | Celldex Therapeutics, Inc. | Gezielte immunostimulierung mit bispezifischen stoffen |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| DE69214709T2 (de) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | Neue Antikörper und Verfahren zu ihrer Verwendung |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| JP2002510968A (ja) * | 1997-05-07 | 2002-04-09 | ブリストル−マイヤーズ スクイブ カンパニー | 組換え抗体−酵素融合タンパク質 |
| MXPA01007845A (es) | 1999-02-05 | 2004-06-22 | Samsung Electronics Co Ltd | Metodo para la recuperacion de la textura de imagenes y aparato para el mismo. |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| WO2004050867A1 (en) * | 2002-12-02 | 2004-06-17 | Seattle Genetics, Inc. | MODIFIED L49-sFv EXHIBITING INCREASED STABILITY AND METHODS OF USE THEREOF |
| US20060160174A1 (en) | 2002-12-02 | 2006-07-20 | Mcdonagh Charlotte F | Modified l49-sfv exhibiting increased stability and methods of use thereof |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| WO2007008603A1 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| DK1912671T3 (da) | 2005-07-18 | 2017-11-27 | Seattle Genetics Inc | Beta-glucuronid-linker-lægemiddelkonjugater |
| DK2099823T4 (da) | 2006-12-01 | 2022-05-09 | Seagen Inc | Målbindingsmiddelvarianter og anvendelser deraf |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| WO2016149535A1 (en) * | 2015-03-18 | 2016-09-22 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
| AU2018282094B2 (en) * | 2017-06-05 | 2024-06-27 | Janssen Biotech, Inc. | Antibodies that specifically bind PD-1 and methods of use |
| MY207630A (en) * | 2018-07-03 | 2025-03-06 | Fennec Pharmaceuticals Inc | Formulations of anhydrous sodium thiosulfate |
| US20230270877A1 (en) * | 2020-11-08 | 2023-08-31 | Seagen Inc. | Combination Therapy |
-
2020
- 2020-02-03 US US16/780,711 patent/US11617798B2/en active Active
- 2020-02-03 EP EP20709016.8A patent/EP3920968A1/en active Pending
- 2020-02-03 WO PCT/US2020/016381 patent/WO2020163225A1/en not_active Ceased
- 2020-02-03 CN CN202080026997.1A patent/CN113710271B/zh active Active
- 2020-02-03 MX MX2021009138A patent/MX2021009138A/es unknown
- 2020-02-03 SG SG11202107551WA patent/SG11202107551WA/en unknown
- 2020-02-03 JP JP2021545378A patent/JP7754715B2/ja active Active
- 2020-02-03 KR KR1020217027987A patent/KR20210125511A/ko active Pending
- 2020-02-03 AU AU2020219732A patent/AU2020219732A1/en active Pending
- 2020-02-03 BR BR112021015477A patent/BR112021015477A2/pt unknown
- 2020-02-04 TW TW109103363A patent/TWI872044B/zh active
-
2021
- 2021-07-19 IL IL284974A patent/IL284974A/en unknown
-
2023
- 2023-02-21 US US18/172,123 patent/US20240033369A1/en not_active Abandoned
-
2024
- 2024-05-07 US US18/657,397 patent/US20240409658A1/en not_active Abandoned
-
2025
- 2025-02-12 JP JP2025021046A patent/JP2025072613A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106459200B (zh) | 抗-egfr抗体及抗体药物偶联物 | |
| AU2019320336B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| EP3909580A1 (en) | Combination of antibody-drug conjugate with parp inhibitor | |
| CN120137038A (zh) | 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法 | |
| CN110545846A (zh) | 用于光免疫疗法的治疗组合物和相关方法 | |
| JP2017534253A5 (enExample) | ||
| JP2019532023A5 (enExample) | ||
| EP3804764A1 (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate | |
| JPWO2020163225A5 (enExample) | ||
| WO2023222135A9 (en) | A method of treating solid tumor | |
| CA3101906C (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate | |
| JPWO2021173832A5 (enExample) | ||
| JP2025513620A (ja) | 抗体－薬物コンジュゲートとｅｚｈ１阻害剤および／またはｅｚｈ２阻害剤との組合せ | |
| TW202408584A (zh) | 抗體-藥物結合物與抗SIRPα抗體之組合 | |
| RU2025111318A (ru) | АНТИ-αvβ6 АНТИТЕЛА И КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| EA050611B1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина | |
| HK40043732A (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| HK40086585A (en) | Combination of (anti-her2 antibody)-drug conjugate and her dimerization inhibitor | |
| WO2020225282A1 (fr) | Adc pour un traitement concomitant ou postérieur au docétaxel | |
| JPWO2023057534A5 (enExample) |